A method for determining one or more properties of a molecular metal ligand in a sample comprises the steps of: providing a quantum sensor: exposing the quantum sensor to the sample: applying an illumination signal to the quantum sensor for a first predetermined duration: and detecting a photoluminescence intensity emitted from the quantum sensor. A characteristic of the detected photoluminescence intensity is indicative of one of the properties of the molecular metal ligand in the sample.

A method for determining one or more properties of a molecular metal ligand in a sample comprises the steps of: providing a quantum sensor: exposing the quantum sensor to the sample: applying an illumination signal to the quantum sensor for a first predetermined duration: and detecting a photoluminescence intensity emitted from the quantum sensor. A characteristic of the detected photoluminescence intensity is indicative of one of the properties of the molecular metal ligand in the sample.

In certain aspects, the present invention provides methods for dosing a patient with a follistatin antagonist and methods for managing patients treated with a follistatin antagonist.

In certain aspects, the present invention provides methods for dosing a patient with a follistatin antagonist and methods for managing patients treated with a follistatin antagonist.

Described are immunoassay kits having a conjugate structure separate from an immunochromatographic strip in which the conjugate structure is freeze-dried with uniform droplet size, and related compositions and methods. The unique structure of the kits described here permits sample containing analyte to be reacted uniformly with the conjugate structure before being subjected to immunochromatography by application to the strip. This results in improved performance of the assay. In addition, the freeze-dried conjugate structure can be stored without contamination and is easy to carry. In addition, the freeze-dried conjugate structure can be rapidly and uniformly dissolved so that it is immediately allowed to react with a mixture of a buffer and a sample, the reaction product then being analyzed by immunochromatography, making it suitable for use in point-of-care testing.

The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload while inhibitors of hepcidin can be used in the treatment of anaemia.

The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload while inhibitors of hepcidin can be used in the treatment of anaemia.

Compositions for treating disorders of iron homeostasis are provided. More particularly, anti-ferroportin antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.

Compositions for treating disorders of iron homeostasis are provided. More particularly, anti-ferroportin antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.

Provided herein are systems and methods of assessing a concentration of iron in a body fluid sample, such as whole blood. Systems include a highly stable, fast reacting, and accurate sensing area of a sensor for contacting with a body fluid sample, wherein upon contact, the body fluid sample causes a color change to the sensor that correlates with the concentration of iron in the body fluid sample. The disclosed systems and methods generate one or more signal outputs of light intensity data, from which the concentration of iron in the body fluid sample is determined.